Kotanagi H, Fukuda K, Ogata N, Takahashi M, Masuda T, Koyama K, Takahashi T
Jpn J Surg. 1987 Jan;17(1):47-50. doi: 10.1007/BF02470585.
The effects of the monoclonal antibody-mitomycin C conjugate against human colon cancers were studied, in vitro and in vivo. Mitomycin C (MMC) was conjugated with the human colon cancer-specific monoclonal antibody, using a cyanogen bromide method. The effect of the conjugate and free MMC, in vitro, was measured by incubation with human colon cancer SW1116 cells. The MMC concentration of the conjugate and of free MMC needed for 50 per cent killing of target cells was 0.11 microgram/ml and 7.00 micrograms/ml, respectively. The effect of the conjugate and of free MMC, in vivo, was assayed by the growth inhibition of human colon cancer xenografted in nude mice, after intraperitoneal injections of 30 micrograms MMC/kg. Antitumor effects of the conjugate against the cancer in nude mice were significantly more potent than that of free MMC.
研究了单克隆抗体-丝裂霉素C偶联物对人结肠癌的体内外作用。采用溴化氰法将丝裂霉素C（MMC）与人结肠癌特异性单克隆抗体偶联。通过与人结肠癌SW1116细胞孵育来测定偶联物和游离MMC的体外作用。使靶细胞50%死亡所需的偶联物和游离MMC的MMC浓度分别为0.11微克/毫升和7.00微克/毫升。通过腹腔注射30微克MMC/千克后对裸鼠体内移植的人结肠癌生长抑制来测定偶联物和游离MMC的体内作用。偶联物对裸鼠体内癌症的抗肿瘤作用明显强于游离MMC。
